Prostate Cancer
Home / Prostate Cancer
Prostate Cancer
Traditionally hormone-driven, prostate cancer therapy has advanced beyond androgen deprivation.
- Androgen Receptor Pathway Inhibitors: abiraterone (Zytiga®), enzalutamide (Xtandi®), apalutamide (Erleada®), and darolutamide (Nubeqa®) prolong survival in both metastatic hormone-sensitive and castration-resistant disease.
- Radioligand Therapy: Pluvicto® (lutetium Lu 177 vipivotide tetraxetan) delivers targeted radiation to PSMA-positive cancer cells.
- PARP Inhibitors: Olaparib and rucaparib show benefit in BRCA1/2-mutated or HRR- deficient tumors.
Your Financial Contribution Can Help Us Fund Critical Programs & Initiatives
As a Nonprofit organization, we are deeply committed to raising awareness, providing patient support, and advocating for research for individuals living with various disease states.
Quick Links
Rare Diseases
Contact Us
For general questions about our organization, our mission, or how you can get involved, please email us. We endeavor to respond to all inquiries